Related Articles
NUCLEAR TYPE-II [H-3] ESTRADIOL BINDING-SITES IN MCF-7 HUMAN BREAST-CANCER CELLS - BINDING INTERACTIONS WITH 2,6-BIS-([3,4-DIHYDROXYPHENYL]-METHYLENE)CYCLOHEXANONE ESTERS AND INHIBITION OF CELL-PROLIFERATION
Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation.
IMPAIRED ACTIVATION OF TUMORICIDAL FUNCTION IN MACROPHAGES FROM MAMMARY-TUMOR BEARERS - THE ROLE OF IFN-GAMMA
A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines
Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model